Evidence map›Paper›PMID 32588394›Full record

ArticleInternational journal of hematology2020

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity.

Giovanni Caocci, Marco Vignetti, Andrea Patriarca, Massimo Breccia, Uwe Platzbecker, Giuseppe A Palumbo, Reinhard Stauder, Francesco Cottone, Duska Petranovic, Maria Teresa Voso and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Giovanni CaocciDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Marco VignettiData Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.
Andrea PatriarcaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Division of Hematology, Sapienza University, Rome, Italy.
Uwe PlatzbeckerClinic and Policlinic of Hematology and Cellular Therapy, Oncology and Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
Giuseppe A PalumboDipartimento di Scienze Mediche, Chirurgiche E Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.
Reinhard StauderDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.
Francesco CottoneData Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.
Duska PetranovicDepartment of Hematology, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Maria Teresa VosoDepartment of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy.
Agostino TafuriAzienda Ospedaliera Sant' Andrea, Rome, Italy.
Rosangela InvernizziDepartment of Internal Medicine, San Matteo IRCCS Policlinic Foundation, University of Pavia, Pavia, Italy.
Jo CaersDepartment of Hematology, CHU de Liège, University of Liege, Liege, Belgium.
Mario LuppiDepartment of Medical and Surgical Sciences, Chair of Hematology, AOU Modena, University of Modena and Reggio Emilia, Modena, Italy.
Giorgio La NasaDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Pasquale NiscolaHematology Unit, Sant' Eugenio Hospital, Rome, Italy.
Fabio EfficaceData Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy. f.efficace@gimema.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.

Indexed as

Patient Outcome AssessmentAgedBiomarkersFemaleFerritinsHumansMaleMiddle AgedMyelodysplastic SyndromesQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesBiomarkersFerritinsFunctional statusMyelodysplastic syndromesQuality of lifeSerum ferritinSymptomsTransfusions

Identifiers

PMID32588394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.